pharma · Vascular Dementia · Angioimmunoblastic T-cell Lymphoma · NBP
NovaBridge Biosciences
NovaBridge Biosciences is a pharma organization headquartered in Rockville, USA. It trades on NYSE under ticker NBP. Primary therapeutic focus areas include Vascular Dementia, Angioimmunoblastic T-cell Lymphoma, Breast C
Rockville, USA HQ
2016 Founded
26 Employees
Public company Type
NBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Rockville, USA
- Founded
- 2016
- Employees
- 26
- Programs
- 4
- Drugs
- 7
- Patents
- 0
mitoxantrone liposome 16 and azacitidine
Phase 2 · small molecule · Angioimmunoblastic T-cell Lymphoma
mitoxantrone liposome 16 and azacitidine for Angioimmunoblastic T-cell Lymphoma is a Phase 2 program (small_molecule) at NovaBridge Biosciences with 1 ClinicalTrials.gov record(s).
Internal code MitAITL
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NovaBridge Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Angioimmunoblastic T-cell Lymphoma
- Status
- active
- Trials
- 1